Basic Information
Kivexa
Regulatory Information
EMEA/H/C/000581
December 16, 2004
37
November 27, 2023
Company Information
the netherlands
Van Asch van Wijckstraat 55H 3811 LP Amersfoort
ViiV Healthcare BV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg. Before initiating treatment with abacavir, screening for carriage of the HLA-B\*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B\*5701 allele.
Overview Summary
Kivexa is used with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). Kivexa contains two active substances, abacavir and lamivudine.